Lv4
490 积分 2022-04-19 加入
Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial
9天前
已完结
Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial
9天前
已完结
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
1个月前
已完结
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
1个月前
已完结
New Approaches to Chronic Hepatitis B
1个月前
已完结
Noncanonical translation of circRNAs drive antitumor immunity
9个月前
已关闭
HBV genotypes and chronicification of acute hepatitis B: more questions than answers
1年前
已完结
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
1年前
已完结
Classic and exertional heatstroke
2年前
已完结
皖公网安备34019202002308
